Rigel Pharmaceuticals RIGL
-
-
-
已收盤：-
本益比明細
年季 | 收盤價 | 本業佔比% | 本益比(近四季) | 每股稅後盈餘(元) | 營業利益(千) | 稅後純益(百萬) |
|---|---|---|---|---|---|---|
| 2026Q2 | 39.12 | 96.76 | 1.99 | 0.88 | 23,575 | 17 |
| 2026Q1 | 27.04 | 90.79 | 1.37 | 0.44 | 11,885 | 9 |
| 2025Q4 | 42.83 | 94.91 | 2.12 | 14.1 | 23,170 | 268 |
| 2025Q3 | 28.33 | 96.29 | 4.49 | 1.47 | 28,420 | 28 |
| 2025Q2 | 18.73 | 98.78 | 3.42 | 3.28 | 61,103 | 60 |
| 2025Q1 | 17.99 | 95.58 | 8.64 | 0.63 | 12,773 | 11 |
| 2024Q4 | 16.82 | 96.96 | 16.95 | 0.81 | 16,655 | 14 |
| 2024Q3 | 16.18 | 97.07 | 73.35 | 0.71 | 14,056 | 12 |
| 2024Q2 | 8.22 | 44.74 | -0.06 | 447 | -1 | |
| 2024Q1 | 14.8 | 109.3 | -0.47 | -6,966 | -8 | |
| 2023Q4 | 14.5 | 74.36 | 0.05 | 1,966 | 1 | |
| 2023Q3 | 10.8 | 117.72 | -0.33 | -4,465 | -6 | |
| 2023Q2 | 12.9 | 111.17 | -0.36 | -5,267 | -7 | |
| 2023Q1 | 13.2 | 103.19 | -0.8 | -12,725 | -14 | |
| 2022Q4 | 15 | 82.89 | 0.06 | 2,079 | 1 | |
| 2022Q3 | 11.8 | 101.05 | -1.1 | -18,403 | -19 | |
| 2022Q2 | 11.3 | 100.33 | -0.8 | -12,965 | -13 | |
| 2022Q1 | 29.9 | 100.08 | -1.6 | -26,261 | -27 | |
| 2021Q4 | 26.5 | 100.07 | -1.4 | -21,418 | -23 | |
| 2021Q3 | 36.3 | 100.07 | -1.2 | -19,785 | -21 |